Chimeric Antigen Receptor Delivery Approaches in the Era of Regulatory-Approved T-cell Products for Cancer Immunotherapy

authors:

avatar Setareh Dashti Shokoohi 1 , avatar Mehdi Sheikhi 2 , avatar Pouya Safarzadeh Kozani ORCID 3 , avatar Pooria Safarzadeh Kozani ORCID 1 , avatar Mehdi Rabiee Valashedi 3 , avatar Chia Bamshad 3 , avatar Amirsadegh Nikoo 3 , avatar Abdolkarim Sheikhi ORCID 4 , *

Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Faculty of Medicine, Islamic Azad University, Kazeroon Branch, Kazeroon, Iran
Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran
Department of Immunology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
Trends in Medical Sciences: Vol.3, issue 1; e131916
published online: June 3, 2023
article type: Letter
received: May 14, 2023
revised: May 21, 2023
accepted: May 21, 2023
DOI: https://doi.org/10.5812/tms-131916

how to cite: Dashti Shokoohi S, Sheikhi M, Safarzadeh Kozani P , Safarzadeh Kozani P, Rabiee Valashedi M, et al. Chimeric Antigen Receptor Delivery Approaches in the Era of Regulatory-Approved T-cell Products for Cancer Immunotherapy. J Adv Immunopharmacol. 2023;3(1):e131916. https://doi.org/10.5812/tms-131916.

References

  • 1.

    Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M. Viral vectors: A look back and ahead on gene transfer technology. New Microbiol. 2013;36(1):1-22. [PubMed ID: 23435812].

  • 2.

    Levine BL. Performance-enhancing drugs: Design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther. 2015;22(2):79-84. [PubMed ID: 25675873]. https://doi.org/10.1038/cgt.2015.5.

  • 3.

    Shen-Ong GL, Potter M, Mushinski JF, Lavu S, Reddy EP. Activation of the c-myb locus by viral insertional mutagenesis in plasmacytoid lymphosarcomas. Science. 1984;226(4678):1077-80. [PubMed ID: 6093260]. https://doi.org/10.1126/science.6093260.

  • 4.

    Varmus HE, Quintrell N, Ortiz S. Retroviruses as mutagens: insertion and excision of a nontransforming provirus alter expression of a resident transforming provirus. Cell. 1981;25(1):23-36. [PubMed ID: 6268304]. https://doi.org/10.1016/0092-8674(81)90228-2.

  • 5.

    Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4(132):132ra53. [PubMed ID: 22553251]. [PubMed Central ID: PMC4368443]. https://doi.org/10.1126/scitranslmed.3003761.

  • 6.

    Ivics Z. Potent CAR-T cells engineered with Sleeping Beauty transposon vectors display a central memory phenotype. Gene Ther. 2021;28(1-2):3-5. [PubMed ID: 32139891]. https://doi.org/10.1038/s41434-020-0138-8.

  • 7.

    Chicaybam L, Abdo L, Viegas M, Marques LVC, de Sousa P, Batista-Silva LR, et al. Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion. Gene Ther. 2020;27(1-2):85-95. [PubMed ID: 31919448]. https://doi.org/10.1038/s41434-020-0121-4.

  • 8.

    Querques I, Mades A, Zuliani C, Miskey C, Alb M, Grueso E, et al. A highly soluble Sleeping Beauty transposase improves control of gene insertion. Nat Biotechnol. 2019;37(12):1502-12. [PubMed ID: 31685959]. [PubMed Central ID: PMC6894935]. https://doi.org/10.1038/s41587-019-0291-z.

  • 9.

    Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, et al. Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Invest. 2020;130(11):6021-33. [PubMed ID: 32780725]. [PubMed Central ID: PMC7598053]. https://doi.org/10.1172/JCI138473.

  • 10.

    Foster JB, Barrett DM, Kariko K. The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy. Mol Ther. 2019;27(4):747-56. [PubMed ID: 30819612]. [PubMed Central ID: PMC6453504]. https://doi.org/10.1016/j.ymthe.2019.01.018.

  • 11.

    Li W, Qiu S, Chen J, Jiang S, Chen W, Jiang J, et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity. 2020;53(2):456-470 e6. [PubMed ID: 32758419]. https://doi.org/10.1016/j.immuni.2020.07.011.

  • 12.

    Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. JAMA Netw Open. 2020;3(4). e202072. [PubMed ID: 32250433]. [PubMed Central ID: PMC7136832]. https://doi.org/10.1001/jamanetworkopen.2020.2072.